TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TherapeuticsMD Announces Third Quarter 2022 Financial Results
November 14, 2022 4:05 PM EST
- Q3 total revenue of $20.9 million -
- ANNOVERA TRx growth of 10% year-over-year -
- Reduced operating expenses by $22 million year-over-year -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TXMD or the Company) (NASDAQ: TXMD), an innovative, leading womens healthcare company, today reported financial results for the third quarter ended September 30, 2022.
Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for... More
